Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT

Background: The addition of adjuvant trastuzumab to chemotherapy has significantly improved outcomes for people with human epidermal growth factor receptor 2 (HER2)-positive, early, potentially curable breast cancer. Twelve months’ trastuzumab, tested in registration trials, was adopted as standard...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Helena Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes-Davies, Daniel Rea, Donna Howe, Kerry Raynes, Helen B Higgins, Maggie Wilcox, Chris Plummer, Betania Mahler-Araujo, Elena Provenzano, Anita Chhabra, Sophie Gasson, Claire Balmer, Jean E Abraham, Carlos Caldas, Peter Hall, Bethany Shinkins, Christopher McCabe, Claire Hulme, David Miles, Andrew M Wardley, David A Cameron, Janet A Dunn
Formato:	Artigo
Idioma:	Inglês
Publicado em:	NIHR Journals Library 2020-08-01
coleção:	Health Technology Assessment
Assuntos:	trastuzumab duration early breast cancer her2-positive adjuvant and neoadjuvant therapy disease-free survival
Acesso em linha:	https://doi.org/10.3310/hta24400
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!